DZD8586 for relapsed or refractory CLL/SLL
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new oral drug called DZD8586 for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or not responded to previous treatment. The goal is to see if it can help control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have CLL or SLL that needs treatment and has returned or not responded to prior therapy.
- You must be able to care for yourself and be up and about at least half of the day (ECOG score 0-2).
- Your bone marrow and major organs must be working well enough.
- You need to agree to use birth control as required.
- You cannot have certain other medical conditions, like active infections, heart problems, or recent cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, DZD8586, against other standard treatments for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or stopped responding to prior therapy. The goal is to see if DZD8586 works better or has fewer side effects.
This study tests a new targeted drug (DZD8586) in combination with other therapies for people who have just been diagnosed with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and have not yet received any treatment. The goal is to see if this combination works better than current standard treatments.
This trial tests TQB3909 tablets in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has returned or did not respond to prior treatment. The goal is to see if the drug is safe and can shrink the cancer or improve control of the disease.
This trial tests a combination of two targeted drugs (zanubrutinib and sonrotoclax) as a first treatment for people with high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL). It aims to see if this approach works better than standard care by using a test called MRD to guide treatment duration.
This trial tests a new drug called lacutoclax (LP-108) in patients whose chronic lymphocytic leukemia or small lymphocytic lymphoma has stopped responding to previous treatments. The drug is designed to work differently than prior therapies and may help patients whose cancer has come back or become resistant to standard care.
This trial tests a new combination treatment (DZD8586) for people with diffuse large B-cell lymphoma (DLBCL). It looks at how well the drug works and how safe it is for both newly diagnosed patients and those whose cancer returned after initial treatment.
Hear when a new Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.